After finishing at $7.57 in the prior trading day, AbCellera Biologics Inc. (NASDAQ: ABCL) closed at $7.43, down -1.85%. In other words, the price has decreased by -$0.14 from its previous closing price. On the day, 1569991 shares were traded. ABCL stock price reached its highest trading level at $7.47 during the session, while it also had its lowest trading level at $7.24.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Ratios:
Our goal is to gain a better understanding of ABCL by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.76 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.78. For the most recent quarter (mrq), Quick Ratio is recorded 8.70 and its Current Ratio is at 8.70. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
On December 15, 2022, Goldman started tracking the stock assigning a Buy rating and target price of $30.
On November 16, 2022, Truist started tracking the stock assigning a Buy rating and target price of $29.Truist initiated its Buy rating on November 16, 2022, with a $29 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 16 when Thermopylae Holdings Ltd. bought 85,102 shares for $10.10 per share. The transaction valued at 859,249 led to the insider holds 55,859,493 shares of the business.
Thermopylae Holdings Ltd. bought 200,000 shares of ABCL for $2,292,460 on Aug 19. The 10% Owner now owns 55,844,391 shares after completing the transaction at $11.46 per share. On Jun 14, another insider, Thermopylae Holdings Ltd., who serves as the 10% Owner of the company, bought 9,173 shares for $8.05 each. As a result, the insider paid 73,842 and bolstered with 55,644,391 shares of the company.
Valuation Measures:
As of this moment, AbCellera’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.95. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.49. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.59 while its Price-to-Book (P/B) ratio in mrq is 1.72.
Stock Price History:
Over the past 52 weeks, ABCL has reached a high of $14.97, while it has fallen to a 52-week low of $5.42. The 50-Day Moving Average of the stock is 9.47, while the 200-Day Moving Average is calculated to be 10.55.
Shares Statistics:
The stock has traded on average 1.78M shares per day over the past 3-months and 1.76M shares per day over the last 10 days, according to various share statistics. A total of 286.31M shares are outstanding, with a floating share count of 203.83M. Insiders hold about 19.70% of the company’s shares, while institutions hold 46.90% stake in the company. Shares short for ABCL as of Jan 30, 2023 were 19.13M with a Short Ratio of 22.17M, compared to 15.15M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 6.69% and a Short% of Float of 12.49%.
Earnings Estimates
Its stock is currently analyzed by 8 different market analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0.09 and a low estimate of -$0.1, while EPS last year was $0.19. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.11 and low estimates of -$0.18.
Analysts are recommending an EPS of between $0.94 and $0.5 for the fiscal current year, implying an average EPS of $0.64. EPS for the following year is -$0.45, with 8 analysts recommending between -$0.33 and -$0.77.
Revenue Estimates
9 analysts predict $50.8M in revenue for the current quarter. It ranges from a high estimate of $88M to a low estimate of $22.49M. As of the current estimate, AbCellera Biologics Inc.’s year-ago sales were $139.33M, an estimated decrease of -63.50% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $14.76M, a decrease of -95.30% less than the figure of -$63.50% in the same quarter last year. There is a high estimate of $17.65M for the next quarter, whereas the lowest estimate is $11.87M.
A total of 10 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $551M, while the lowest revenue estimate was $486.38M, resulting in an average revenue estimate of $517.63M. In the same quarter a year ago, actual revenue was $375.2M, up 38.00% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $107.65M in the next fiscal year. The high estimate is $256M and the low estimate is $39.8M. The average revenue growth estimate for next year is down -79.20% from the average revenue estimate for this year.
